☆ 4.7 Article

Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials

ALZHEIMERS & DEMENTIA (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial

Agnetha D. Fruijtier et al.

Summary: This study investigated the impact of six communication strategies on amyloid disclosure in mild cognitive impairment (MCI) patients. It found that risk communication best practices resulted in the highest information recall, while recall in emotional support was better than the basic and elaborate information strategies. Risk communication best practices also led to the highest uncertainty, while teach-back and emotional support contributed to the highest evaluations of the physician and information. Overall, risk communication best practices, attending to emotions, and teach-back techniques enhance information recall and contribute to positive care evaluations for amyloid-PET results.

ALZHEIMERS & DEMENTIA (2023)

Add to Collection

Article Clinical Neurology

Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum

Emily A. Largent et al.

Summary: Alzheimer's Disease (AD) is characterized by three pathologic processes: beta-amyloid, hyperphosphorylated tau, and neurodegeneration. Advances in measuring biomarkers of these processes have led to a growing interest in using AD biomarker tests in care and research. Therefore, a 5-step approach is proposed, including determining the appropriateness of testing, providing pretest education and consent, administering the test, disclosing the results, and follow-up for well-being.

NEUROLOGY (2023)

Add to Collection

Editorial Material Clinical Neurology

Disclosing Alzheimer Disease Biomarker Results to Research Participants

Joshua D. Grill et al.

JAMA NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Development and design of a diagnostic report to support communication in dementia: Co-creation with patients and care partners

Aniek M. M. van Gils et al.

Summary: This study aimed to develop a personalized diagnostic report through a mixed-methods approach, involving surveys and focus group discussions with patients and care partners. The majority of participants valued the diagnostic report for summarizing test results in a brief and straightforward manner, including brain imaging and future expectations. Co-creation was identified as highly valuable in meeting the specific needs of end-users during the iterative design process.

ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2022)

Add to Collection

Article Clinical Neurology

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society

Claire M. Erickson et al.

Summary: This article explores the broader social implications of disclosing Alzheimer's disease biomarkers and identifies challenges and preliminary solutions.

ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2022)

Add to Collection

Article Clinical Neurology

Development and design of a diagnostic report to support communication in dementia: Co-creation with patients and care partners

Aniek M. van Gils et al.

Summary: In this study, a personalized diagnostic report was successfully designed through co-creation with patients and care partners. Most participants agreed that the report should be brief, straightforward, and include diagnostic test results, including brain imaging.

ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2022)

Add to Collection

Article Clinical Neurology

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society

Claire M. Erickson et al.

Summary: This article discusses the broader social implications of disclosing Alzheimer's disease biomarkers to cognitively unimpaired adults, identifying 10 challenges and offering preliminary solutions. With the field continuing to evolve, it is crucial to anticipate and address these broader ethical, legal, and social implications of disclosure.

ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2022)

Add to Collection

Article Geriatrics & Gerontology

Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results

Emily A. Largent et al.

Summary: The study found that most participants understood and valued the AD dementia risk information they received. Positive risk information elicited feelings of happiness and relief, while negative information led to disappointment and increased awareness of cognitive changes.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2021)

Add to Collection

Article Clinical Neurology

Disclosure of individual research results at federally funded Alzheimer's Disease Research Centers

J. Scott Roberts et al.

Summary: This study found that Alzheimer's Disease Research Centers varied widely in how they disclosed research results to participants, with diagnostic and cognitive test results being more commonly returned than genetic or biomarker results.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2021)

Add to Collection

Article Geriatrics & Gerontology

Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study

Taisei Wake et al.

AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS (2020)

Add to Collection

Article Clinical Neurology

A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment

Jennifer H. Lingler et al.

ALZHEIMERS & DEMENTIA (2020)

Add to Collection

Article Clinical Neurology

Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment

Joshua D. Grill et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials

Carolyn M. Langlois et al.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)

Add to Collection

Article Geriatrics & Gerontology

Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials

Joshua D. Grill et al.

NEUROBIOLOGY OF AGING (2016)

Add to Collection

Review Clinical Neurology

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Clifford R. Jack et al.

NEUROLOGY (2016)

Add to Collection

Review Clinical Neurology

Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials

Scott Y. H. Kim et al.

NEUROLOGY (2015)

Add to Collection

Article Clinical Neurology

Targeting Prodromal Alzheimer Disease With Avagacestat A Randomized Clinical Trial

Vladimir Coric et al.

JAMA NEUROLOGY (2015)

Add to Collection

Article Psychiatry

Effect of Knowledge of APOE Genotype on Subjective and Objective Memory Performance in Healthy Older Adults

Tara T. Lineweaver et al.

AMERICAN JOURNAL OF PSYCHIATRY (2014)

Add to Collection

Article Geriatrics & Gerontology

Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment

Vanessa Lawrence et al.

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2014)

Add to Collection

Article Clinical Neurology

Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline

Michael Grundman et al.

ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2013)

Add to Collection

Article Clinical Neurology

Impact of molecular imaging on the diagnostic process in a memory clinic

Rik Ossenkoppele et al.

ALZHEIMERS & DEMENTIA (2013)

Add to Collection

Article Medicine, General & Internal

International Work Group Criteria for the Diagnosis of Alzheimer Disease

Jeffrey L. Cummings et al.

MEDICAL CLINICS OF NORTH AMERICA (2013)

Add to Collection

Article Clinical Neurology

Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues

J. Scott Roberts et al.

NEURODEGENERATIVE DISEASE MANAGEMENT (2013)

Add to Collection

Article Clinical Neurology

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Marilyn S. Albert et al.

ALZHEIMERS & DEMENTIA (2011)

Add to Collection

Article Clinical Neurology

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study

Serena Chao et al.

ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.